Latest news with #Reviva
Yahoo
25-06-2025
- Business
- Yahoo
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ('Reviva' or the 'Company'), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes. The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the 'SEC') on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC's website at Copies of the preliminary prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. Forward-Looking Statements This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering and uncertainties related to the size, timing, completion, and use of proceeds from the proposed offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company's Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. REVIVA CONTACTS: Corporate Contact:Reviva Pharmaceuticals Holdings, Bhat, Investor Relations Contact:LifeSci Advisors, LLCPJ Kelleherpkelleher@
Yahoo
25-06-2025
- Business
- Yahoo
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
CUPERTINO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ('Reviva' or the 'Company'), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it intends to offer shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock in a public offering. All of the securities to be sold in the offering are to be offered by Reviva. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering. The Company currently intends to use the net proceeds from the offering to fund research and development activities and for working capital and other general corporate purposes. The securities will be offered pursuant to an effective shelf registration statement on Form S-3 (File No. 333-276848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the 'SEC') on February 2, 2024, and declared effective by the SEC on February 13, 2024. A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC's website at Copies of the preliminary prospectus supplement and accompanying base prospectus, when available, may be obtained from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, NY 10022, or by telephone at (212) 624-2060, or by email at prospectus@ This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Reviva Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva's pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries. Forward-Looking Statements This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, risks associated with market conditions and the satisfaction of customary closing conditions related to the proposed offering and uncertainties related to the size, timing, completion, and use of proceeds from the proposed offering. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's prospectus supplement to be filed with the SEC, and the documents incorporated by reference therein, including the Company's Form 10-K for the year ended December 31, 2024 and Form 10-Q for the quarter ended March 31, 2025. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. REVIVA CONTACTS: Corporate Contact:Reviva Pharmaceuticals Holdings, Bhat, Investor Relations Contact:LifeSci Advisors, LLCPJ Kelleherpkelleher@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fibre2Fashion
01-05-2025
- Business
- Fibre2Fashion
Shyamlal Patnaik
Liva Reviva-M is the first-of-its-kind circular fibre As the global textile industry shifts towards circularity and low-impact production, innovation in sustainable fibres has never been more critical. Birla Cellulose, a global leader in man-made cellulosic fibres, is at the forefront of this transformation. In this interview with Fibre2Fashion, Shyamlal Patnaik, Joint President – Global Head Specialty Business at Birla Cellulose, discusses the company's pioneering efforts in advancing its specialty fibre portfolio, with a spotlight on Liva Reviva-M—the company's latest breakthrough in circular fibre innovation. He shares insights on sustainability gains, supply chain adaptability, and how Birla Cellulose is scaling solutions for a more responsible fashion ecosystem. As head of the specialty business, what is your approach to innovating within Birla Cellulose's diverse fibre portfolio? As the demand for natural fibres continues to grow, it is important to highlight the evolving benefits of man-made cellulosic fibres. Our approach to innovation is rooted in sustainability, circularity, and enhancing the functional properties of fibres. Our specialty fibre portfolio reflects this focus, delivering performance and eco-conscious solutions for a wide range of applications. How is Birla Cellulose responding to changing dynamics in the global textile supply chain? With new geopolitical challenges, including trade tariffs, addressing the global textile supply chain has become critical to ensuring business continuity. We are well-positioned to meet customer demand across different regions, thanks to our manufacturing units located in multiple geographies. This enables us to adapt more swiftly to the evolving supply chain landscape. What are your priorities when it comes to scaling sustainable specialty fibres across categories? We are strongly committed to scaling our sustainable specialty fibres. To support this, we are launching our state-of-the-art Liva Reviva-M manufacturing unit in Nagda, which will produce Liva Reviva-M fibre. This new facility marks our latest advancement in circular fibre innovation. What makes Liva Reviva-M a breakthrough innovation in the recycled cellulosic fibre space? Liva Reviva-M is an extension of our Reviva product category, specially crafted based on customer preferences. It is the first-of-its-kind circular fibre that uses post-consumer textile waste—such as used clothing— as feedstock. Can you explain the technical process behind mechanically opening post-consumer cotton-rich waste and blending it with Birla MMCF fibres like Excel and Spunshade? The process is uniquely developed through our in-house innovation, where we are uniformly blending mechanically recycled textile waste fibres with our sustainable Birla fibres, such as Excel and Spunshade, based on customer specifications. The uniqueness of this process lies in its customisability, allowing us to create tailored fibre blends that come with certifications like GRS, FSC, and, we will be introducing the fibre with tracers in the future. How do you ensure quality, consistency, and fibre performance while using mixed post-consumer waste as input? Quality and consistency are critical. Our blending process ensures a uniform, customised fibre blend that meets customer requirements and enhances performance. The post-consumer textile waste is sourced with full traceability at the point of collection and is GRS-certified, RSL-compliant (free from hazardous chemicals), and includes detailed information on the blend ratio. What are the sustainability gains in terms of chemical, water, and energy savings during Liva Reviva-M's production? Liva Reviva-M is the first circular fibre that does not consume any additional chemicals or water and is produced using low energy. This makes it a highly sustainable fibre with a low carbon footprint. In terms of product application, how does Liva Reviva-M perform in heavier categories like recycled denim and terry towels? Liva Reviva-M is ideal for producing heavyweight textile fabrics. We are currently offering two categories: Liva Liva Reviva-M (Denim) for recycled denim applications, and Liva Reviva-M (White) for terry towels and other fabrics, based on customer requirements. How does Liva Reviva-M compare with existing fibres in the LIVA Reviva line from a functionality and processability standpoint? 'Reviva' means 'reviving back to new life.' Liva Reviva-M is a mechanically blended fibre and an extension of the Reviva range. While we already offer Liva Reviva fibres through a chemical recycling process using recycled pulp to produce sustainable viscose or lyocell fibres, Liva Reviva-M is specifically designed for heavyweight fabric applications such as recycled denim and terry towels. What is your strategy for scaling production and encouraging mill and brand adoption of Liva Reviva-M globally? Our Liva Reviva-M plant in Nagda has a production capacity of up to 5KT per year. As adoption of Liva Reviva-M grows, we are prepared to scale up the capacity further. We are actively collaborating with mills and brands to develop products using Liva Reviva-M and to offer consumers sustainable and circular textile options. DISCLAIMER: All views and opinions expressed in this column are solely of the interviewee, and they do not reflect in any way the opinion of
Arab News
03-03-2025
- Business
- Arab News
Saudi Arabia's PIF-backed SIRC launches solid waste plant at Jeddah Port
RIYADH: Saudi Investment Recycling Co. has launched the first solid waste treatment plant inside Jeddah Islamic Port, marking a significant step toward sustainability and a circular economy. The Public Investment Fund-owned firm will operate the facility through its subsidiary, Reviva, to enhance operational efficiency and safety, according to a statement. The initiative aligns with Saudi Arabia's Vision 2030 goal of achieving net-zero emissions by 2060 and integrating environmental, social, and governance principles into the economy. It also supports Reviva's mission to divert 85 percent of industrial waste from landfills through treatment and recycling while promoting the use of reprocessed materials. Reviva CEO Nasser Al-Mutairi described the plant's launch as a strategic step reflecting SIRC's commitment to innovative, sustainable waste management solutions. The facility enables on-site treatment of solid and non-compliant waste per international standards, eliminating the need for external transport. The CEO further highlighted this directly reduces environmental impact and supports the shift away from landfills, reinforcing the principles of a circular economy while enhancing financial and environmental sustainability. Reviva leads the industrial hazardous waste sector, advancing recycling practices and landfill diversion to meet the Kingdom's sustainability goals. Its core services include integrated environmental solutions and services, recycling and waste management solutions such as oil and water recovery, byproduct recycling, industrial maintenance, and environmental testing and studies. The project is part of SIRC's broader strategy to expand investment in the recycling sector and build an integrated waste management infrastructure. It also creates job opportunities and increases private sector involvement in waste management initiatives. Additionally, SIRC is developing integrated environmental projects at Jeddah Islamic Port, including specialized sites for hazardous waste treatment from cargo ships. These efforts aim to improve marine waste management, promote sustainability, and strengthen Saudi Arabia's position as a global leader in waste management and recycling.
Leaders
30-01-2025
- Business
- Leaders
NCVC Announces Investment Opportunities in Firewood Recycling, Plant Management
The National Center for Vegetation Cover Development and Combating Desertification (NCVC) has announced new investment opportunities aimed at recycling reclaimed firewood from logging violations and repurposing invasive plant species into alternative economic products. According to a press release, these initiatives seek to foster public-private collaboration in addressing environmental challenges, generate economic value from reclaimed wood and invasive plants, and promote innovative solutions that support both sustainability and economic growth. The initiative also contributes to the long-term preservation of forests, rangelands, and ecosystems while creating job opportunities through the use of invasive plant wood in various industries. NCVC invites associations, companies, and government entities specializing in recycling, craftsmanship, manufacturing, organic products, construction, and transformative industries to apply via its official website. Applications are open until mid-February. Investors must comply with environmental regulations and executive bylaws on logging violations, which strictly prohibit the direct use or resale of firewood as fuel. 'As part of its commitment to sustainable development, NCVC continues to provide both long-term and seasonal investment opportunities to expand vegetation cover, support afforestation projects, conserve natural resources, and enhance quality of life,' the statement added. These efforts align with the Saudi Green Initiative and Vision 2030, contributing to national economic growth and job creation. Related Topics : Warning: SR2,000 Fines for Unlicensed Camping in Saudi Arabia Saudi National Day 2024: The Kingdom Blooms in Green Environmental Experts Highlight Saudi Initiatives at FAO Event Mawani, Reviva to Establish Complex for Recycling Marine Waste at Jeddah Islamic Port Short link : Post Views: 34
